Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BE6A LUNG-02 first-line sigvotatug vedotin plus pembrolizumab versus pembrolizumab in PD-L1-high advanced NSCLC
MOH_2025-05-15_013912Phase 3Not yet recruiting
- Sponsor
- Pfizer
- Start
- Apr 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sigvotatug vedotin and pembrolizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Pfizer. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
sigvotatug vedotinpembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on MOH_2025-05-15_013912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-05-15_013912.